Compare FMC Corp (FMC) vs Humana Inc (HUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FMC Corp vs Humana Inc — how do they compare? FMC Corp trades at $8.89 (market cap $1.41B), while Humana Inc trades at $444.98 (market cap $47.61B). The key difference: Humana Inc is far larger — about 33.8× FMC Corp's market cap, and FMC Corp pays the higher dividend (3.52%). Which is the better fit depends on your goals — on Pluang, investors hold FMC Corp for 68 Days and Humana Inc for 53 Days on average.
| FMC | HUM | |
|---|---|---|
Market Cap | $1.41B | $47.61B |
Volume | 4,507,459 | 1,827,332 |
Sector | Basic Materials | Health |
52-Week High | $30.63 | $409.85 |
52-Week Low | $8.44 | $163.67 |
Typical Hold Time | 68 Days | 53 Days |
Enterprise Value | $5.22B | $54.97B |
Dividend Yield | 3.52% | 0.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FMC trades at $8.92, down 1.22% on the day, with a bearish technical signal and negative profitability metrics including a net income margin of -84.83% and ROE of -91.47% for 2025. Recent news highlights regulatory progress with rimisoxafen in Brazil and a minority equity investment from Tessenderlo Group. Cash flow trends show volatility, with 2025 net cash flow positive at $227.20M but driven by financing activities as operating cash flow was negative.
The outlook is challenged by significant losses and high debt, though analyst consensus suggests upside with a $14.60 price target. Key risks include sustained negative margins, industry cyclicality, and execution of deleveraging plans. The stock presents a high-risk opportunity contingent on operational turnaround and debt reduction success.
Humana (HUM) trades at $387.12, down 4.24% today, but maintains a bullish technical outlook with strong institutional support. The stock shows mixed fundamentals with revenue growth to $129.66B in 2025 but declining profit margins at 0.88%. Recent analyst upgrades, including Barclays' $515 target on September 25, 2026, highlight optimism despite ongoing Medicare Advantage plan adjustments affecting member transitions.
Investment outlook remains cautiously optimistic with a consensus price target of $432.63 offering 12% upside. Risks include margin compression, regulatory scrutiny from Medicare billing practices, and competitive pressures in managed care. The company's strong cash position of $20.44B and consistent dividend payments provide stability amid enrollment volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FMC Corp
FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.
Read more on FMC →About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →
